SCHEDULE: State Street Discloses Viridian Therapeutics Stake

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 4,876,395 shares, or 4.3%, of Viridian Therapeutics Inc. common stock as of September 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Viridian Therapeutics Inc. common stock.
• As of September 30, 2026, State Street Corporation beneficially owns 4,876,395 shares of common stock.
• This represents 4.3% of the total class of securities.
• The filing indicates shared voting power for 4,633,744 shares and shared dispositive power for 4,876,395 shares.
• State Street Corporation is classified as a 'HC' (likely referring to a holding company or financial institution) and is filing under Rule 13d-1(b).
• Several subsidiaries of State Street Global Advisors are identified as entities involved in the ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine disclosure of beneficial ownership by an institutional investor and does not contain new operational or financial performance information.

Positives

• State Street Corporation's investment indicates confidence from a major financial institution in Viridian Therapeutics.
• The disclosure is a standard regulatory filing, ensuring transparency for investors.

Negatives

• The filing does not provide any new operational or financial performance data for Viridian Therapeutics.
• The information is purely a disclosure of ownership, offering no insight into the company's strategic direction or performance.

Risks

• The filing does not explicitly mention any risks related to Viridian Therapeutics' operations or market position.
• The primary risk associated with this type of filing is the potential for future changes in ownership by large institutional investors, which could impact stock price volatility.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Viridian Therapeutics' future performance. It is a disclosure of current ownership status.

Management Comments

• Alok Maheshwary, Senior Vice President at State Street Corporation, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like State Street Corporation when their ownership stake in a public company crosses a certain threshold. This filing indicates State Street's role as a significant, though not controlling, shareholder in the biotechnology sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Creditors: No direct impact as the filing does not concern debt or financial distress.
• Employees: No direct impact as the filing is purely a financial disclosure.
• Suppliers/Customers: No direct impact as the filing does not relate to operational changes.

Next Steps

• State Street Corporation will continue to monitor its holdings and may file amendments to this Schedule 13G if there are material changes in its beneficial ownership.
• Viridian Therapeutics Inc. will continue its business operations as disclosed in its other filings.

Key Dates

Keywords

State Street Corporation, Viridian Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Securities Exchange Act